DUBLIN--(BUSINESS WIRE)--The "Antithrombin Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
The report predicts the global antithrombin market to grow with a CAGR of 5% over the forecast period of 2018-2024. The report on antithrombin market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global antithrombin market over the period of 2016 to 2024.
The report finds that the widespread of antithrombin for several medical conditions such as hereditary antithrombin deficiency, extracorporeal membrane oxygenation is primarily driving the global antithrombin market. The currently approved antiplatelet agent, clopidogrel, has satisfied some of these requirements and has played a large role in expanding the antithrombotic market over the past few years. However, the pharmaceutical industry has taken a huge effort to develop antithrombotic that functions by inhibiting key enzymes positioned at higher levels of the coagulation system.
Additionally, use of antithrombin with heparin will prove more beneficial in treatment of the patients suffering from antithrombin disorders. However, price concerns associated with antithrombin over alternatives is likely to restrain the growth of the antithrombin market. The increase in adoption of newer technologies and advanced products in developing countries are providing huge growth opportunities for the key players in the antithrombin market. Moreover, research based applications is gaining grip to discover new disease indication.
Key Topics Covered
2. Executive Summary
3. Global Antithrombin Market Overview
4. Global Antithrombin Market by Application
5. Global Antithrombin Market by Source
6. Global Antithrombin Market by Formulation
7. Global Antithrombin Market by Region 2018-2024
8. Companies Covered
- Scripps Laboratories Inc.
- Diapharma Group Inc.
- Lee Bisolutions Inc.
- Dem ilac Inc.
- Octapharma AG
- Kedrion S.p.A.
- CSL Limited
- Shire Plc
- rEVO Biologics Inc.
For more information about this report visit https://www.researchandmarkets.com/research/66xns5/global?w=4